CPEB4 modulates liver cancer progression by translationally regulating hepcidin expression and sensitivity to ferroptosis

Background & Aims: Liver cancer is a significant global health issue, with its incidence rising in parallel with the obesity epidemic. The limited therapeutic options available emphasize the need for a better understanding of the molecular pathways involved in its pathogenesis. While much of...

Full description

Saved in:
Bibliographic Details
Main Authors: M. Eugenia Delgado, Salvador Naranjo-Suarez, Marta Ramírez-Pedraza, Beatriz I. Cárdenas, Carmen Gallardo-Martínez, Alexandra Balvey, Eulalia Belloc, Judit Martín, Mark Boyle, Raúl Méndez, Mercedes Fernandez
Format: Article
Language:English
Published: Elsevier 2025-03-01
Series:JHEP Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2589555924003008
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832557497058066432
author M. Eugenia Delgado
Salvador Naranjo-Suarez
Marta Ramírez-Pedraza
Beatriz I. Cárdenas
Carmen Gallardo-Martínez
Alexandra Balvey
Eulalia Belloc
Judit Martín
Mark Boyle
Raúl Méndez
Mercedes Fernandez
author_facet M. Eugenia Delgado
Salvador Naranjo-Suarez
Marta Ramírez-Pedraza
Beatriz I. Cárdenas
Carmen Gallardo-Martínez
Alexandra Balvey
Eulalia Belloc
Judit Martín
Mark Boyle
Raúl Méndez
Mercedes Fernandez
author_sort M. Eugenia Delgado
collection DOAJ
description Background &amp; Aims: Liver cancer is a significant global health issue, with its incidence rising in parallel with the obesity epidemic. The limited therapeutic options available emphasize the need for a better understanding of the molecular pathways involved in its pathogenesis. While much of the previous research has focused on transcriptional changes, this study examines translational alterations, specifically the role of cytoplasmic polyadenylation element binding protein 4 (CPEB4), a key regulator of translation. Methods: We analyzed publicly available patient databases and conducted studies using human and mouse liver cancer cells, xenograft and allograft models, mouse models of high-fat diet-related liver cancer, and CPEB4 knockout and knockdown mice and cell lines. Results: Patient data analysis (n = 87) showed a strong correlation between low CPEB4 levels and reduced survival rates (p <0.001). In mouse models of diet-induced liver cancer (n = 10–15 per group), both systemic and hepatocyte-specific CPEB4 knockout mice exhibited significantly increased tumor burden compared with wild-type controls (p <0.05). In vitro studies using human and murine liver cancer cells (n = 3 biological replicates) demonstrated reduced sensitivity to ferroptosis upon CPEB4 depletion when induced by erastin or RSL3 (p <0.01). Mechanistically, CPEB4 deficiency suppressed hepcidin expression, leading to elevated ferroportin levels, decreased intracellular iron accumulation, and reduced lipid peroxidation (p <0.05). Conclusions: This study uncovers a novel CPEB4-dependent mechanism linking translational control to liver cancer progression and ferroptosis regulation. Therapeutic strategies targeting CPEB4-mediated pathways hold promise for advancing treatment options in liver cancer. Impact and implications:: This study addresses the pressing need for improved therapies in liver cancer, particularly given its increasing prevalence linked to obesity and metabolic-associated fatty liver disease. By uncovering the role of the RNA-binding protein cytoplasmic polyadenylation element binding protein 4 (CPEB4) in modulating iron regulation and cancer cell sensitivity to ferroptosis, our research highlights a new translational mechanism with potential therapeutic relevance. These findings are particularly significant for clinicians, researchers, and policymakers focused on advancing targeted treatments for hepatocellular carcinoma. If further validated in human clinical studies, targeting CPEB4-mediated pathways could help develop treatments that enhance cancer cell susceptibility to ferroptosis, offering a promising strategy for improving outcomes in patients with advanced liver cancer. Limitations of the study include the need for further clinical validation to confirm these preclinical findings in human disease contexts.
format Article
id doaj-art-25f7182793ae4224af16903418894afc
institution Kabale University
issn 2589-5559
language English
publishDate 2025-03-01
publisher Elsevier
record_format Article
series JHEP Reports
spelling doaj-art-25f7182793ae4224af16903418894afc2025-02-03T04:16:52ZengElsevierJHEP Reports2589-55592025-03-0173101296CPEB4 modulates liver cancer progression by translationally regulating hepcidin expression and sensitivity to ferroptosisM. Eugenia Delgado0Salvador Naranjo-Suarez1Marta Ramírez-Pedraza2Beatriz I. Cárdenas3Carmen Gallardo-Martínez4Alexandra Balvey5Eulalia Belloc6Judit Martín7Mark Boyle8Raúl Méndez9Mercedes Fernandez10FRCB-IDIBAPS Biomedical Research Institute; Barcelona, SpainFRCB-IDIBAPS Biomedical Research Institute; Barcelona, SpainFRCB-IDIBAPS Biomedical Research Institute; Barcelona, SpainFRCB-IDIBAPS Biomedical Research Institute; Barcelona, SpainFRCB-IDIBAPS Biomedical Research Institute; Barcelona, SpainFRCB-IDIBAPS Biomedical Research Institute; Barcelona, SpainInstitute for Research in Biomedicine (IRB), The Barcelona Institute of Science and Technology, Barcelona, SpainInstitute for Research in Biomedicine (IRB), The Barcelona Institute of Science and Technology, Barcelona, SpainFRCB-IDIBAPS Biomedical Research Institute; Barcelona, SpainInstitute for Research in Biomedicine (IRB), The Barcelona Institute of Science and Technology, Barcelona, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA); Barcelona, Spain; Corresponding author. Address: IDIBAPS, Rosselló Street 149, 08036 Barcelona, Spain. Tel.: +34-606958606.FRCB-IDIBAPS Biomedical Research Institute; Barcelona, Spain; Corresponding author. Address: IDIBAPS, Rosselló Street 149, 08036 Barcelona, Spain. Tel.: +34-606958606.Background &amp; Aims: Liver cancer is a significant global health issue, with its incidence rising in parallel with the obesity epidemic. The limited therapeutic options available emphasize the need for a better understanding of the molecular pathways involved in its pathogenesis. While much of the previous research has focused on transcriptional changes, this study examines translational alterations, specifically the role of cytoplasmic polyadenylation element binding protein 4 (CPEB4), a key regulator of translation. Methods: We analyzed publicly available patient databases and conducted studies using human and mouse liver cancer cells, xenograft and allograft models, mouse models of high-fat diet-related liver cancer, and CPEB4 knockout and knockdown mice and cell lines. Results: Patient data analysis (n = 87) showed a strong correlation between low CPEB4 levels and reduced survival rates (p <0.001). In mouse models of diet-induced liver cancer (n = 10–15 per group), both systemic and hepatocyte-specific CPEB4 knockout mice exhibited significantly increased tumor burden compared with wild-type controls (p <0.05). In vitro studies using human and murine liver cancer cells (n = 3 biological replicates) demonstrated reduced sensitivity to ferroptosis upon CPEB4 depletion when induced by erastin or RSL3 (p <0.01). Mechanistically, CPEB4 deficiency suppressed hepcidin expression, leading to elevated ferroportin levels, decreased intracellular iron accumulation, and reduced lipid peroxidation (p <0.05). Conclusions: This study uncovers a novel CPEB4-dependent mechanism linking translational control to liver cancer progression and ferroptosis regulation. Therapeutic strategies targeting CPEB4-mediated pathways hold promise for advancing treatment options in liver cancer. Impact and implications:: This study addresses the pressing need for improved therapies in liver cancer, particularly given its increasing prevalence linked to obesity and metabolic-associated fatty liver disease. By uncovering the role of the RNA-binding protein cytoplasmic polyadenylation element binding protein 4 (CPEB4) in modulating iron regulation and cancer cell sensitivity to ferroptosis, our research highlights a new translational mechanism with potential therapeutic relevance. These findings are particularly significant for clinicians, researchers, and policymakers focused on advancing targeted treatments for hepatocellular carcinoma. If further validated in human clinical studies, targeting CPEB4-mediated pathways could help develop treatments that enhance cancer cell susceptibility to ferroptosis, offering a promising strategy for improving outcomes in patients with advanced liver cancer. Limitations of the study include the need for further clinical validation to confirm these preclinical findings in human disease contexts.http://www.sciencedirect.com/science/article/pii/S2589555924003008TranslationCytoplasmic polyadenylation element binding proteinFerroptotic cell deathHepatocellular carcinoma
spellingShingle M. Eugenia Delgado
Salvador Naranjo-Suarez
Marta Ramírez-Pedraza
Beatriz I. Cárdenas
Carmen Gallardo-Martínez
Alexandra Balvey
Eulalia Belloc
Judit Martín
Mark Boyle
Raúl Méndez
Mercedes Fernandez
CPEB4 modulates liver cancer progression by translationally regulating hepcidin expression and sensitivity to ferroptosis
JHEP Reports
Translation
Cytoplasmic polyadenylation element binding protein
Ferroptotic cell death
Hepatocellular carcinoma
title CPEB4 modulates liver cancer progression by translationally regulating hepcidin expression and sensitivity to ferroptosis
title_full CPEB4 modulates liver cancer progression by translationally regulating hepcidin expression and sensitivity to ferroptosis
title_fullStr CPEB4 modulates liver cancer progression by translationally regulating hepcidin expression and sensitivity to ferroptosis
title_full_unstemmed CPEB4 modulates liver cancer progression by translationally regulating hepcidin expression and sensitivity to ferroptosis
title_short CPEB4 modulates liver cancer progression by translationally regulating hepcidin expression and sensitivity to ferroptosis
title_sort cpeb4 modulates liver cancer progression by translationally regulating hepcidin expression and sensitivity to ferroptosis
topic Translation
Cytoplasmic polyadenylation element binding protein
Ferroptotic cell death
Hepatocellular carcinoma
url http://www.sciencedirect.com/science/article/pii/S2589555924003008
work_keys_str_mv AT meugeniadelgado cpeb4modulateslivercancerprogressionbytranslationallyregulatinghepcidinexpressionandsensitivitytoferroptosis
AT salvadornaranjosuarez cpeb4modulateslivercancerprogressionbytranslationallyregulatinghepcidinexpressionandsensitivitytoferroptosis
AT martaramirezpedraza cpeb4modulateslivercancerprogressionbytranslationallyregulatinghepcidinexpressionandsensitivitytoferroptosis
AT beatrizicardenas cpeb4modulateslivercancerprogressionbytranslationallyregulatinghepcidinexpressionandsensitivitytoferroptosis
AT carmengallardomartinez cpeb4modulateslivercancerprogressionbytranslationallyregulatinghepcidinexpressionandsensitivitytoferroptosis
AT alexandrabalvey cpeb4modulateslivercancerprogressionbytranslationallyregulatinghepcidinexpressionandsensitivitytoferroptosis
AT eulaliabelloc cpeb4modulateslivercancerprogressionbytranslationallyregulatinghepcidinexpressionandsensitivitytoferroptosis
AT juditmartin cpeb4modulateslivercancerprogressionbytranslationallyregulatinghepcidinexpressionandsensitivitytoferroptosis
AT markboyle cpeb4modulateslivercancerprogressionbytranslationallyregulatinghepcidinexpressionandsensitivitytoferroptosis
AT raulmendez cpeb4modulateslivercancerprogressionbytranslationallyregulatinghepcidinexpressionandsensitivitytoferroptosis
AT mercedesfernandez cpeb4modulateslivercancerprogressionbytranslationallyregulatinghepcidinexpressionandsensitivitytoferroptosis